Stryker Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin A. Lobo
- Full Time Employees
- 56,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1941 Stryker Way Portage MI United States of America 49002
- IPO Date
- Mar 17, 1980
- CIK
- 0000310764
- Website
- stryker.com
- Similar Companies
- Business
- Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?
Is SYK Worth Buying as Growth Improves but Execution Risks Persist?
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
PBH or SYK: Which Is the Better Value Stock Right Now?
Stryker declares an $0.88 per share quarterly dividend
Stryker Q2 Earnings Call Highlights
SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber Recovery
Stryker Corp (SYK) (Q2 2026) Earnings Call Highlights: Strong 9% Organic Growth and Raised Guidance Amid Cyber Recovery
Stryker Corporation (SYK) Q2 2026 Earnings Call Transcript
Stryker (SYK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
Stryker beats quarterly estimates on strong demand for medical devices
Stryker Logs Higher Profit, Revenue Amid Cyberattack Recovery
Stryker reports second quarter 2026 operating results
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
PAHC vs. SYK: Which Stock Is the Better Value Option?
Exploring Analyst Estimates for Stryker (SYK) Q2 Earnings, Beyond Revenue and EPS
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders